Leonidas Nikolaos Diamantopoulos

Dr. Leonidas Nikolaos Diamantopoulos

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2021 in Biology
Verified
Journal Article
Open access
PDF file
MKMarkos Kalligeros
Markos Kalligeros
LDLeonidas Nikolaos Diamantopoulos
Leonidas Nikolaos Diamantopoulos
Christos ToumpanakisChristos Toumpanakis
Christos Toumpanakis
Biomarkers remain a valuable tool for the diagnosis and management of Neuroendocrine tumors (NETs). Traditional monoanalyte biomarkers such as Chromogranin A (CgA) and 5-Hydrocyondoleacetic acid (5-HIAA) have been widely used for many years as diagnostic, predictive and prognostic biomarkers in the field of NETs. However, the clinical utility of these molecules often has limitations, mainly inherent to the heterogeneity of NETs and the fact that these tumors can often be non-secretory. The development of new molecular multianalyte biomarkers, especially the mRNA transcript based “NETest”, has rapidly evolve the field and gives the ability for a “liquid biopsy” which can reliably assess disease status in real time. In this review we discuss the use of established and novel biomarkers in the diagnosis and management of small intestine NETs and carcinoid heart disease.

30 July 2023 in Biology
Verified
Journal Article
Open access
PDF file
LDLeonidas Nikolaos Diamantopoulos
Leonidas Nikolaos Diamantopoulos
MKMarkos Kalligeros
Markos Kalligeros
Thorvardur HalfdanarsonThorvardur Halfdanarson
Thorvardur Halfdanarson
NDNikolaos Diamantis
Nikolaos Diamantis
Christos ToumpanakisChristos Toumpanakis
Christos Toumpanakis
There is an evolving landscape of systemic combination regimens for patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). In this review, we provide a comprehensive outline of the existing clinical trials/prospective studies investigating these combinations. PubMed was searched using key relevant terms to identify articles referring to GEP-NETs and combination treatments. No systematic search of the literature or metanalysis of the data was performed, and we focused on the most recent literature results. Primarily, phase 1 and 2 clinical trials were available, with a smaller number of phase 3 trials, reporting results from combination treatments across a wide range of antiproliferative agents. We identified significant variability in the anti-tumor activity of the reported combinations, with occasional promising results, but only a very small number of practice-changing phase 3 clinical trials. Overall, the peptide receptor radionuclide therapy (PRRT)-based combinations (with chemotherapy, dual PPRT, and targeted agents) and anti-vascular endothelial growth factor (VEGF) agent combinations with standard chemotherapy were found to have favorable results and may be worth investigating in future, larger-scale trials. In contrast, the immune-checkpoint inhibitor-based combinations were found to have limited applicability in advanced, well-differentiated GEP-NETs.

15 March 2023 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
LDLeonidas Nikolaos Diamantopoulos
Leonidas Nikolaos Diamantopoulos
DMDimitrios Makrakis
Dimitrios Makrakis
DKDimitrios Korentzelos
Dimitrios Korentzelos
MAMichail Alevizakos
Michail Alevizakos
JWJonathan L. Wright
Jonathan L. Wright
GTGregory Tripsianis
Gregory Tripsianis

20 May 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AKAli Raza Khaki
Ali Raza Khaki
LDLeonidas Nikolaos Diamantopoulos
Leonidas Nikolaos Diamantopoulos
ALAng Li
Ang Li
MDMichael Devitt
Michael Devitt
ADAlexandra Drakaki
Alexandra Drakaki
PGPetros Grivas
Petros Grivas
4525 Background: Anti-PD(L)1 immune checkpoint inhibitors (ICI) prolong overall survival (OS) after platinum chemotherapy in mUC. However, clinical outcomes in pts with poor PS at time of ICI initiation are unknown. We hypothesized that ICI initiation in pts with ECOG PS 2-3 would be associated with worse outcomes vs. pts with ECOG PS < 2, and impact death location. Methods: A retrospective cohort study in 8 institutions identified pts with mUC who received ICI. Demographic, clinicopathologic, treatment (tx) patterns, tx response, and outcomes were collected. Primary endpoint: overall response rate (ORR). Secondary endpoints: median (m) OS in pts receiving ICI as 1st and 2nd line (1L, 2L); odds of dying in hospital (vs elsewhere) for pts receiving ICI (vs no tx) within 30 days of death; and estimated drug cost for pts with ICI within 30 days of death based on average wholesale price. Unadjusted logistic regression was used to assess association between ORR and ECOG PS (2-3 vs < 2) and wald test was used to compare mOS between ECOG PS (2-3 vs < 2). Results: 194 consecutive pts (30% women, 41% never smokers, median age at diagnosis 69) treated with ICI for mUC were identified. Median number of total tx lines was 2; all pts received ≥1 ICI line (6 pts received 2 ICI lines); 97, 79, 17 and 7 pts received ICI in 1L, 2L, 3L and 4L, respectively; 26% pts with ICI in 1L and 2L had ECOG PS 2-3. ORR and mOS are shown in table. Among 106 pts who died, 96 had available death location; of those, 8% received ICI within 30 days of death. Starting ICI within 30 days of death (vs no tx) was associated with higher odds of hospital death (OR 6.05, 95%CI 1.3-27.6). Estimated average ICI cost/pt within 30 days of death was $1400.58. Conclusions: Pts with ECOG PS 2-3 at time of ICI initiation had similar ORR vs ECOG PS < 2 but worse mOS. ICI initiation within 30 days from death was associated with higher likelihood of hospital death. ICI may not circumvent the negative prognostic role of poor PS, so biomarker-based pt selection is critical. Limitations include lack of adjustment for selection bias and other confounders at time of ICI initiation; data validation is ongoing. [Table: see text]